SYROS PHARMACEUTICALS INC (SYRS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SYRS • US87184Q2066

0.1172 USD
-0.01 (-8.44%)
At close: Mar 19, 2025
0.1072 USD
-0.01 (-8.53%)
After Hours: 3/19/2025, 8:16:43 PM
Fundamental Rating

1

SYRS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. SYRS has a bad profitability rating. Also its financial health evaluation is rather negative. SYRS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • SYRS had negative earnings in the past year.
  • In the past year SYRS has reported a negative cash flow from operations.
  • SYRS had negative earnings in each of the past 5 years.
  • In the past 5 years SYRS always reported negative operating cash flow.
SYRS Yearly Net Income VS EBIT VS OCF VS FCFSYRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -115.08%, SYRS is doing worse than 78.77% of the companies in the same industry.
Industry RankSector Rank
ROA -115.08%
ROE N/A
ROIC N/A
ROA(3y)-61.3%
ROA(5y)-54.72%
ROE(3y)-387.81%
ROE(5y)-270.29%
ROIC(3y)N/A
ROIC(5y)N/A
SYRS Yearly ROA, ROE, ROICSYRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

  • SYRS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SYRS Yearly Profit, Operating, Gross MarginsSYRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

  • SYRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SYRS has more shares outstanding
  • SYRS has a worse debt/assets ratio than last year.
SYRS Yearly Shares OutstandingSYRS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
SYRS Yearly Total Debt VS Total AssetsSYRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -16.26, we must say that SYRS is in the distress zone and has some risk of bankruptcy.
  • SYRS has a Altman-Z score of -16.26. This is amonst the worse of the industry: SYRS underperforms 82.98% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.26
ROIC/WACCN/A
WACC9.28%
SYRS Yearly LT Debt VS Equity VS FCFSYRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 2.25 indicates that SYRS has no problem at all paying its short term obligations.
  • SYRS has a worse Current ratio (2.25) than 72.98% of its industry peers.
  • SYRS has a Quick Ratio of 2.25. This indicates that SYRS is financially healthy and has no problem in meeting its short term obligations.
  • SYRS has a Quick ratio of 2.25. This is in the lower half of the industry: SYRS underperforms 71.23% of its industry peers.
Industry RankSector Rank
Current Ratio 2.25
Quick Ratio 2.25
SYRS Yearly Current Assets VS Current LiabilitesSYRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 19.20% over the past year.
  • The Revenue for SYRS has decreased by -95.61% in the past year. This is quite bad
  • The Revenue has been growing by 37.12% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)19.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.81%
Revenue 1Y (TTM)-95.61%
Revenue growth 3Y-13%
Revenue growth 5Y37.12%
Sales Q2Q%-100%

3.2 Future

  • SYRS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.05% yearly.
  • Based on estimates for the next years, SYRS will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y73.44%
EPS Next 2Y35.34%
EPS Next 3Y23.72%
EPS Next 5Y7.05%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-47.5%
Revenue Next 5Y-14.87%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SYRS Yearly Revenue VS EstimatesSYRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2026 2027 2031 2032 5M 10M 15M 20M
SYRS Yearly EPS VS EstimatesSYRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SYRS. In the last year negative earnings were reported.
  • Also next year SYRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYRS Price Earnings VS Forward Price EarningsSYRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYRS Per share dataSYRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SYRS's earnings are expected to grow with 23.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.34%
EPS Next 3Y23.72%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for SYRS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYROS PHARMACEUTICALS INC / SYRS FAQ

What is the ChartMill fundamental rating of SYROS PHARMACEUTICALS INC (SYRS) stock?

ChartMill assigns a fundamental rating of 1 / 10 to SYRS.


What is the valuation status of SYROS PHARMACEUTICALS INC (SYRS) stock?

ChartMill assigns a valuation rating of 0 / 10 to SYROS PHARMACEUTICALS INC (SYRS). This can be considered as Overvalued.


What is the profitability of SYRS stock?

SYROS PHARMACEUTICALS INC (SYRS) has a profitability rating of 0 / 10.


Can you provide the financial health for SYRS stock?

The financial health rating of SYROS PHARMACEUTICALS INC (SYRS) is 2 / 10.